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World Health Organization (WHO) Classifications of Tumors have historically pro-vided a global standard for tumor diagnosis. Familiarity with these classifications 
is essential for clinicians because they provide the foundation for accurate patient diagno-
sis and optimal medical management. In addition, the diagnostic terminology and criteria 
recommended by the WHO should be incorporated into study design of clinical trials and 
molecular studies such as The Cancer Genome Atlas (TCGA). WHO Classifications are 
periodically updated to incorporate important advances to make them relevant to current 
knowledge and clinical practice. The 2015 WHO Classification of Tumors of the Lung, 
Pleura, Thymus and Heart has just been published1 and the Journal of Thoracic Oncology 
will be publishing a series of articles summarizing key points about the new classification 
outlining the major changes from the 2004 classification.2–4† The International Association 
for Research on Cancer (IARC) under the leadership of Dr. Hiroko Ohgaki coordinated 
this project and was the publisher of this book. IARC hosted a consensus meeting in Lyon, 
France, April 24–26, 2014, where all major changes in the classification from the 2004 
book were discussed and approved (Figure).
The 2015 WHO Classification features the incorporation of many exciting new 
advances in thoracic tumor diagnosis and classification. It was formulated by a multidisci-
plinary group of international experts with broad international representation.
The primary changes in the lung classification, which are highlighted in the first 
paper in this series,3 relate to lung cancer where over the past decade remarkable progress 
in genetics and therapy has had a major impact on tumor classification. These most sig-
nificant changes are consequent to the 2011 IASLC/ATS/ERS Classification5 including 
recommendations for routine molecular testing and use of immunohistochemistry, a new 
approach to small biopsies and cytology and a novel way of subtyping of surgically resected 
lung adenocarcinomas that has provided a powerful new tool for identifying prognostic and 
molecular correlations. Large scale genomic studies from the TCGA6,7 and Clinical Lung 
Cancer Genome Project8 provided a strong genetic foundation for reclassification of squa-
mous cell carcinoma, adenocarcinoma and large cell carcinoma. These changes have major 
clinical relevance as histologic type and genetics are now driving personalized medicine for 
lung cancer patients. New concepts in adenocarcinoma classification with lepidic versus 
invasive patterns are also having an impact on the approach to tumor size measurement for 
TNM staging of small tumors ≤3cm and therefore the surgical management of patients. 
Support from the IASLC, through their Pathology Committee and by providing multidisci-
plinary input, contributed greatly to the development of this classification.5,9
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The thymic tumor classification, to be published in 
October,2 makes minor changes to the 2004 thymoma classi-
fication maintaining the type A, AB, B1, B2, and B3 types. 
However, considerable effort was made in collaboration with 
the International Thymic Malignancy Interest Group (ITMIG) 
to incorporate a multidisciplinary approach and to make refine-
ments to sharpen diagnostic criteria. One new aspect is to rec-
ognize histological criteria that are “obligatory/indispensible”, 
and others that are “optional”. In addition, it is recognized that 
mixed patterns are frequent in thymomas so a proposal is made 
to record these in 10% increments. It is also recognized that all 
thymomas have malignant potential, so these tumors should 
not be regarded as benign. These morphologic observations 
are grounded in new genetic data that provide support for the 
existing classification and potential for deeper insights into the 
molecular characteristics of these tumors.
For tumors of the pleura, the histologic classification 
of malignant mesothelioma remains the same as the 2004 
classification. However, data have suggested that histologic 
subtyping of epithelioid mesothelioma may correlate with 
prognosis; particularly the pleomorphic subtype which 
appears to be is associated with poor prognosis. In addition, 
an expanded role for immunohistochemistry has been defined 
for separating mesothelioma from carcinomas of various 
sites. In addition, more precise criteria have been recognized 
for distinguishing malignant mesothelioma from reactive 
mesothelial proliferations. New data regarding genetics, 
in particular involving the BAP1 gene has led to exciting 
new clinical and molecular studies. Preliminary data also 
suggests that grading of mesotheliomas may have prognostic 
significance. The development of the revision of the pleural 
chapter was greatly facilitated by the French National Health 
Institute (INVS) and the French National Cancer Institute 
(INCA) in supporting the International Mesothelioma Panel 
(IMP) over the past 17 years.
Cardiac tumors are extremely rare, so there are few 
resources to learn about their pathology, genetics and clinical 
features. The manuscript on cardiac tumors, to be published 
in late 2015,4 provides an invaluable review of benign tumors, 
tumors of uncertain biologic behavior, germ cell tumors, and 
malignant tumors. Germ cell tumors within the pericardium 
are typically childhood teratomas without metastatic poten-
tial. The most important cardiac tumors are the sarcomas. The 
molecular and cytogenetic characterization of cardiac sarco-
mas is in progress, and will likely result in significant modifi-
cations to the current classification in years to come.
The editors gratefully acknowledge the wonderful sci-
entific contributions and collegiality of each of the contrib-
uting authors as well as IASLC, ITMIG, IMP, and IARC in 
making publication of this book possible.
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